BSH 2023 | Managing cardiac toxicities associated with BTK inhibitors and selecting between these agents
Talha Munir
• 24 Apr 2023
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, shares some insights into the cardiac toxicities associated with the use of Bruton’s tyrosine kinase (BTK) inhibitors, and further explains factors to consider when selecting between these agents. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
